Baillie Gifford & Co. Sells 195,120 Shares of Recursion Pharmaceuticals, Inc. $RXRX

Baillie Gifford & Co. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 0.8% during the third quarter, HoldingsChannel.com reports. The fund owned 23,978,695 shares of the company’s stock after selling 195,120 shares during the quarter. Baillie Gifford & Co. owned 0.06% of Recursion Pharmaceuticals worth $117,016,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in RXRX. Norges Bank bought a new position in Recursion Pharmaceuticals during the second quarter valued at approximately $16,040,000. Bank Pictet & Cie Europe AG purchased a new stake in Recursion Pharmaceuticals during the 3rd quarter valued at $7,954,000. Geode Capital Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 20.7% during the 2nd quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company’s stock valued at $39,353,000 after buying an additional 1,332,428 shares during the period. First Trust Advisors LP lifted its holdings in shares of Recursion Pharmaceuticals by 82.3% during the 2nd quarter. First Trust Advisors LP now owns 1,880,290 shares of the company’s stock valued at $9,514,000 after buying an additional 848,791 shares during the period. Finally, Vestmark Advisory Solutions Inc. boosted its stake in shares of Recursion Pharmaceuticals by 89.6% in the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 1,339,139 shares of the company’s stock worth $6,776,000 after buying an additional 632,900 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, insider Najat Khan sold 124,403 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total transaction of $548,617.23. Following the transaction, the insider owned 611,135 shares of the company’s stock, valued at $2,695,105.35. The trade was a 16.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Blake Borgeson sold 220,000 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $4.36, for a total transaction of $959,200.00. Following the completion of the sale, the director directly owned 6,649,863 shares of the company’s stock, valued at approximately $28,993,402.68. This trade represents a 3.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 585,786 shares of company stock valued at $2,558,598 over the last 90 days. 8.43% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RXRX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday. UBS Group set a $11.00 price target on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Morgan Stanley set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Finally, JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $10.00 to $11.00 in a research report on Wednesday, December 17th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $4.73 on Friday. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $4.46 and a two-hundred day simple moving average of $5.03. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of -2.63 and a beta of 0.95. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. The firm had revenue of $5.18 million for the quarter, compared to analysts’ expectations of $19.36 million. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The business’s quarterly revenue was down 80.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.34) EPS. On average, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.